Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gaia Herbs helps “brick-and-mortar” outlets

This article was originally published in The Tan Sheet

Executive Summary

Gaia Herbs' win against the antitrust lawsuit filed by "serves to ensure traditional 'brick-and-mortar' natural products stores that competition from online mass market discounters will not factor" into potential sales for the herbal manufacturer's product line, Gaia states in a June 13 release. The U.S. District Court of the Southern District of Florida dismissed the case in March and decided the firm did not violate state antitrust laws by refusing to do business with because the e-commerce firm did not agree to Gaia's mandated minimum resale price for its products (1"The Tan Sheet" April 30, 2007, p. 15). Gaia implemented a policy to not sell its products to online retailers that do not also have brick-and-mortar establishments in January...

You may also be interested in...

Gaia Herbs Suit Dismissal Highlights Antitrust Law Awareness

Dietary supplement firms must be aware of antitrust laws when implementing pricing policies, according to an attorney who represented Gaia Herbs in a lawsuit filed against it by e-commerce firm

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts